Characterization of a Daptomycin-nonsusceptible Vancomycin-intermediate Staphylococcus Aureus Strain in a Patient with Endocarditis

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2007 Jul 11

PMID 17620372

Citations 76

Authors

Kathleen Julian

Klaudia Kosowska-Shick

Cynthia Whitener

Martin Roos

Harald Labischinski

Aileen Rubio

Leslie Parent

Lois Ednie

Laura Koeth

Tatiana Bogdanovich

Peter C Appelbaum

Affiliations

Soon will be listed here.

Abstract

We analyzed the emergence of daptomycin nonsusceptibility in a patient with persistent vancomycin-intermediate Staphylococcus aureus (VISA) bacteremia. The daptomycin-nonsusceptible VISA's cell wall demonstrated a reduction in muramic acid O-acetylation, a phenotypic parameter not previously reported for VISA; some isolates also contained a single point mutation in the mprF gene.

Citing Articles

Population Analysis of Daptomycin-non-Susceptible Methicillin-Resistant Staphylococcus aureus Reveals the Presence of Variants That Contribute to Daptomycin Resistance.

Kanesaka I, Yabuta J, Jitsukawa T, Fujisaki S, Morita M, Mikawa T Curr Microbiol. 2024; 81(2):61.

PMID: 38206417 DOI: 10.1007/s00284-023-03579-4.

Bacterial cell membranes and their role in daptomycin resistance: A review.

Nguyen A, Hood K, Mileykovskaya E, Miller W, Tran T Front Mol Biosci. 2022; 9:1035574.

PMID: 36452455 PMC: 9702088. DOI: 10.3389/fmolb.2022.1035574.

Genome-Wide Association Studies for the Detection of Genetic Variants Associated With Daptomycin and Ceftaroline Resistance in .

Weber R, Fuchs S, Layer F, Sommer A, Bender J, Thurmer A Front Microbiol. 2021; 12:639660.

PMID: 33658988 PMC: 7917082. DOI: 10.3389/fmicb.2021.639660.

Single nucleotide polymorphism leads to daptomycin resistance causing amino acid substitution-T345I in MprF of clinically isolated MRSA strains.

Nakamura M, Kawada H, Uchida H, Takagi Y, Obata S, Eda R PLoS One. 2021; 16(1):e0245732.

PMID: 33481910 PMC: 7822245. DOI: 10.1371/journal.pone.0245732.

Clinical Pharmacokinetics of Daptomycin.

Gregoire N, Chauzy A, Buyck J, Rammaert B, Couet W, Marchand S Clin Pharmacokinet. 2020; 60(3):271-281.

PMID: 33313994 DOI: 10.1007/s40262-020-00968-x.

References

Papakyriacou H, Vaz D, Simor A, Louie M, McGavin M . Molecular analysis of the accessory gene regulator (agr) locus and balance of virulence factor expression in epidemic methicillin-resistant Staphylococcus aureus. J Infect Dis. 2000; 181(3):990-1000. DOI: 10.1086/315342. View

Pillai S, Gold H, Sakoulas G, Wennersten C, Moellering Jr R, Eliopoulos G . Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother. 2007; 51(6):2223-5. PMC: 1891363. DOI: 10.1128/AAC.00202-07. View

Peschel A, JACK R, Otto M, Collins L, Staubitz P, Nicholson G . Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med. 2001; 193(9):1067-76. PMC: 2193429. DOI: 10.1084/jem.193.9.1067. View

Oliveira D, de Lencastre H . Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2002; 46(7):2155-61. PMC: 127318. DOI: 10.1128/AAC.46.7.2155-2161.2002. View

Fridkin S, Hageman J, McDougal L, Mohammed J, Jarvis W, Perl T . Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis. 2003; 36(4):429-39. DOI: 10.1086/346207. View

Staubitz P, Neumann H, Schneider T, Wiedemann I, Peschel A . MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important determinant in staphylococcal defensin resistance. FEMS Microbiol Lett. 2004; 231(1):67-71. DOI: 10.1016/S0378-1097(03)00921-2. View

Appelbaum P, Philippon A, Jacobs M, Spangler S, Gutmann L . Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance. Antimicrob Agents Chemother. 1990; 34(11):2169-76. PMC: 172019. DOI: 10.1128/AAC.34.11.2169. View

Tenover F, Arbeit R, Goering R, Mickelsen P, Murray B, Persing D . Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995; 33(9):2233-9. PMC: 228385. DOI: 10.1128/jcm.33.9.2233-2239.1995. View

Stranden A, Ehlert K, Labischinski H, Berger-Bachi B . Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J Bacteriol. 1997; 179(1):9-16. PMC: 178655. DOI: 10.1128/jb.179.1.9-16.1997. View

10.

Lina G, Piemont Y, Bes M, Peter M, Gauduchon V, Vandenesch F . Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999; 29(5):1128-32. DOI: 10.1086/313461. View

11.

Hayden M, Rezai K, Hayes R, Lolans K, Quinn J, Weinstein R . Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005; 43(10):5285-7. PMC: 1248493. DOI: 10.1128/JCM.43.10.5285-5287.2005. View

12.

Vikram H, Havill N, Koeth L, Boyce J . Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol. 2005; 43(10):5384-7. PMC: 1248502. DOI: 10.1128/JCM.43.10.5384-5387.2005. View

13.

Kosowska-Shick K, Clark C, Credito K, McGhee P, Dewasse B, Bogdanovich T . Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother. 2006; 50(2):765-9. PMC: 1366917. DOI: 10.1128/AAC.50.2.765-769.2006. View

14.

Cui L, Tominaga E, Neoh H, Hiramatsu K . Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006; 50(3):1079-82. PMC: 1426436. DOI: 10.1128/AAC.50.3.1079-1082.2006. View

15.

Patel J, Jevitt L, Hageman J, McDonald L, Tenover F . An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis. 2006; 42(11):1652-3. DOI: 10.1086/504084. View

16.

Friedman L, Alder J, Silverman J . Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2006; 50(6):2137-45. PMC: 1479123. DOI: 10.1128/AAC.00039-06. View

17.

Sader H, Jones R . The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Clin Infect Dis. 2006; 43(6):798-9. DOI: 10.1086/507109. View

18.

Fowler Jr V, Boucher H, Corey G, Abrutyn E, Karchmer A, Rupp M . Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006; 355(7):653-65. DOI: 10.1056/NEJMoa053783. View

19.

Wootton M, MacGowan A, Walsh T, Howe R . A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol. 2006; 45(2):329-32. PMC: 1829006. DOI: 10.1128/JCM.01508-06. View

20.

Trakulsomboon S, Danchaivijitr S, Rongrungruang Y, Dhiraputra C, Susaemgrat W, Ito T . First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J Clin Microbiol. 2001; 39(2):591-5. PMC: 87781. DOI: 10.1128/JCM.39.2.591-595.2001. View